ClinicalTrials.gg
CompletedNCT02538848Updated Aug 11, 2026

Study of HTD4010 in Healthy Volunteers

A Phase 1 interventional study of HTD4010 in Type 2 Diabetes Mellitus, sponsored by HighTide Therapeutics (Hong Kong) Limited. Completed at 1 site in Australia. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by HighTide Therapeutics (Hong Kong) Limited · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

To investigate safety and tolerability of HTD4010 after single ascending doses (SAD) in healthy volunteers

Read the detailed description

Safety, tolerability and pharmacokinetics(PK) assessments are the outcome measure.

02

Conditions studied

  • Type 2 Diabetes Mellitus
03

In context

Diabetes Mellitus, Type 2

10,371 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,406 are open to participants now.

This study's enrollment of 32 is below the median of 80 across 8,350 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

HighTide Therapeutics (Hong Kong) Limited is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For volunteers in SAD:

Inclusion criteria

Inclusion Criteria:

  1. (BMI) ≥18.0 to ≤ 30.0 kg/m2
  2. Non-diabetic, fasting plasma glucose \< 5.6 mmol/L
  3. Females must be non-pregnant and non-lactating, and either surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or for ≥12 months.

    Males must be surgically sterile, abstinent or if engaged in sexual relations of , the participant and his partner must be using an acceptable, highly effective, method from screening and for a period of 60 days after the last dose of Study Drug.

  4. Ability to provide written .

Exclusion criteria

Exclusion Criteria:

  1. Systolic blood pressure >160 mmHg and/or diastolic blood pressure >90 mmHg at screening.
  2. Pregnant or lactating women
  3. Participation in an study within 30 days prior to dosing or 5 half-lives within the last dose of investigational product whichever is longer.
  4. Current use of any prescription or over-the-counter (OTC) medications, including herbal products and supplements, within 14 days prior to Day 1 or 5 half-lives, whichever is longer. Use of ≤2g paracetamol per day is allowed prior to and during the study at Investigator discretion.
  5. Any use of non- anti-inflammatory drugs (NSAIDs) within 7 days prior to dosing.
  6. History of any major surgery within 6 months prior to Screening
  7. History of any serious adverse reaction or to any of the product components.
  8. Use of parenterally administered proteins or antibodies within 12 weeks of screening.

etc.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    50mg in SAD

    single dose of 50mg HTD4010 or placebo injectable in healthy volunteers

    Drug: HTD4010

  • Experimental
    100mg in SAD

    single dose of 100mg HTD4010 or placebo injectable in healthy volunteers

    Drug: HTD4010

  • Experimental
    200mg in SAD

    single dose of 200mg HTD4010 or placebo injectable in healthy volunteers

    Drug: HTD4010

  • Experimental
    300mg in SAD

    single dose of 300mg HTD4010 or placebo injectable in healthy volunteers

    Drug: HTD4010

Interventions

  • DrugHTD4010

    injectable solution

    Also known as: analog of INGAP peptide

06

What researchers measure

Primary outcomes

  1. Incidence, severity and causality of adverse events

    Time frame: One day in SAD

07

Study locations

1 site
  • Linear Clinical Research Limited
    Perth, WA6009, Australia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2015
First posted
Sep 2, 2015
Start
Oct 2015
Primary completionActual
Mar 2016
CompletionActual
Mar 2016
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02538848
Lead sponsor
HighTide Therapeutics (Hong Kong) Limited
Responsible party
Sponsor
First posted
Sep 2, 2015
Start date
Oct 2015
Primary completion
Mar 2016
Completion
Mar 2016
Last update
Aug 11, 2026

Study contacts

Janakan Krishnarajah, Doctor
principal investigator · Linear Clinical Research Limited

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion